Navigation Links
5X Improvement in Z-Motion Range is Big Step Forward for World of Microscopy – N-725 Z-Axis Piezo Positioner by PI
Date:7/19/2013

etail.php?sortnr=1100210&onl_prw

About PI

The PI group provides the broadest and deepest portfolio of precision motion technologies, from micropositioning to sub-nanometer precision positioning equipment for markets as diverse as semiconductor manufacturing, bio-technology, photonics, aerospace and medical engineering. PI has 4 decades of experience with the design and manufacture of precision positioning systems based on piezoceramic and electromagnetic drives. The company has been ISO 9001 certified since 1994 and provides innovative, high-quality solutions for OEM and research. PI is present worldwide with 10 subsidiaries, R&D / engineering on 3 continents and total staff of 750+.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10947525.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. The MedZilla.com Employment Report for July, 2013: Nation's Economy Makes Substantial, Demonstrable Improvements
2. New Analysis Yields Improvements in Classic 3D Imaging Technique
3. ComplianceOnline Announces Seminar on Clinical Trial Project Supplier Quality Improvement
4. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
5. Dr. Ross Kaplan Offers New State-of-the-Art Wrinkle, Fine Line, and Skin Texture Improvement Treatment
6. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
7. REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
8. Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes
9. iLuv Introduces a Range of Accessories to Enhance Apple’s Lightning Devices at 2013 CES
10. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
11. Strange cousins: Molecular alternatives to DNA, RNA offer new insight into lifes origins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Tauriga Sciences, Inc. (OTCQB:  ... sciences company, today announced that its stockholders approved an ... stock of the Company from 1,000,000,000 to 2,500,000,000 at ... 2015 at the Law Offices of Nixon Peabody LLP ... Meeting, there were 480,655,929 shares of common stock represented ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/28/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, ... ) today announced its financial results for the ... ®  sales grew nearly 300% as compared to ... was first launched," said Roger Jeffs, Ph.D., United ... in Orenitram sales was due to an increase ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Dec. 14 The board of,directors of Abbott today declared ... marks the 336th consecutive quarterly dividend to be paid by,Abbott ... to,shareholders of record at the close of business on Jan. ... 35 consecutive years --,including a 10.2 percent increase earlier this ...
... (NYSE: BDY ) today announced its launch ... treatment of,external genital (EGW) and perianal warts (Condylomata ... is the first new,prescription treatment for external genital ... MediGene AG (Frankfurt: MDG) and has exclusive,marketing rights ...
... (NYSE:,FMC) and Pronova BioPharma ASA (OSE: PRON) ... worldwide license and development agreement to develop,products ... FMC. The,alginate-based capsule technology is expected to ... BioPharma,s products and has,the potential for use ...
Cached Biology Technology:Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... April issue of the Journal of the American ... eating plans; dietary quality among children; and relationships between ... Increased Risk of Eating Disorders , While vegetarians tend ... non-vegetarians to be overweight or obese, they may be ...
... the Richard King Trainee Award. This award was instituted last ... to encourage ABMG trainees in their careers and to foster ... year the editorial board will review all articles published in ... or corresponding author during that year. The manuscript felt to ...
... Being able to accurately predict how a given ... non-responsive tumors the burden of undergoing toxic and ultimately ... a patient,s cancer-causing genetic lesions are contributing to drug ... Researchers led by Professor Scott Lowe, Ph.D., ...
Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 3CSHL team develops mouse models of leukemia that predict response to chemotherapy 4
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Biology Products: